Cannabidiol-Drug Interaction in Cancer Patients: A retrospective study in a real-life setting.
Fiche publication
Date publication
février 2023
Journal
British journal of clinical pharmacology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BOUCHE Olivier
Tous les auteurs :
Guedon M, Le Bozec A, Brugel M, Clarenne J, Carlier C, Perrier M, Laurent M, Hettler D, Mongaret C, Bouché O, Slimano F
Lien Pubmed
Résumé
Cannabidiol (CBD) consumption in cancer patients is growing and need to be revealed to identify to detect Cannabidiol-Drug Interaction (CDI). However, CDI and the clinical relevance between CBD, anticancer treatment, supportive care and conventional drugs is poorly studied especially in real-life setting. In one oncology day-hospital a cross-sectional study in 363 cancer patients treated with chemotherapy revealed 20 patients (5.5%) who consumed CBD. In this study we aimed to explore the prevalence and clinical relevance of CDI among these 20 patients. CDI detection and clinically relevance used the FDA Drugs.com database and clinically relevance was assessed accordingly. Ninety CDI with 34 medicines were detected (4.6 CDI CBD-related/patient). The main clinical risks were central nervous system depression and hepatoxicity. Main CDI with CBD were assessed as moderate and anticancer treatment do not seem to add to the risk. CBD discontinuation appears to be the most consistent management. Future studies should explore the clinical relevance of CDI with CBD in cancer patients.
Mots clés
Cannabidiol, Herb-drug interaction, Oncology
Référence
Br J Clin Pharmacol. 2023 02 27;: